PSNL · Personalis, Inc.
Market Cap
$1.74B
Shares
106.80M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$16.21
Open$16.46
Day$16.19–16.58
52W close$5.04–18.38
Avg vol 30d3.3M
Short int8.4M · 7.9% float · 1.8d
Short vol38%
Last earningsJul 20, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 4
Up next
Next earnings call
Oct 11, 2026
Est · unconfirmed
· in 4 wks
filed Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$69.67M
Trailing 12 months
Net income (TTM)
−$107.18M
Trailing 12 months
Revenue growth YoY
+30.0%
Year over year
Operating margin
-164.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+19.1%
Year over year · more shares
Price change (1Y)
+203.0%
Trailing year
Short interest
7.9%
Latest settlement · 1.8 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.60
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+61%
above
Price vs 50-day avg
+10%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
84%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+12%
trailing
6-month return
+123%
trailing
YTD return
+104%
this year
Relative strength
+105%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $15 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.85% of float · ▼ -0.2% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
157 holders — near 3-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
−18%
Y/Y
EPS growth
+34%
Y/Y
Free cash flow
$-79.5M
Balance sheet
$68.5M
net cash
Quant / Vol
risk profile
Volatility
92%
annualized · 1-yr
Max drawdown
−55%
past year
ATR
4.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Total company revenue
· full year 2026
Initiated
$78M – $80M
prior FY $69.65M
midpoint +13.4% Y/Y
Revenue from pharma testing services and all other customers
· full year 2026
Initiated
$55M – $56M
Revenue from population sequencing and enterprise sales
· full year 2026
Initiated
$13M
Gross margin
· full year 2026
Initiated
15% – 20%
Cash usage
· full year 2026
Initiated
$100M
Prior guidance
period ended
· from the 8-K filed Aug 7, 2024
Total company revenue
· third quarter of 2024
$21M – $22M
Revenue from pharma tests, enterprise sales, and other customers
· third quarter of 2024
$17M – $18M
Revenue from population sequencing
· third quarter of 2024
$4M
Total company revenue
· full year of 2024
$79M – $81M
Revenue from pharma tests, enterprise sales, and all other custo
· full year of 2024
$71M – $73M
Cash usage
· full year of 2024
$60M
Guided vs delivered
· last 6 settled
Total company revenue
third quarter of 2024
guided $21M – $22M
$25.71M
Beat +19.6%
Total company revenue
full year of 2024
guided $79M – $81M
$84.61M
Beat +5.8%
Total company revenues
Q4 of 2021
guided $20.2M – $20.4M
$20.68M
Beat +1.9%
Total company revenues
full year of 2021
guided $85M
$85.49M
Beat +0.6%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+61%
Bullish
Price vs 50-day avg
+10%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
84%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $15 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +40 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.85% of float · ▼ -0.2% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
157 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $5
Now $16 · 84%
Range high $18
vs 200-day avg +61%
vs 50-day avg +10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PSNL
this stock
Personalis, Inc.
|
$1.74B | +103.6% | -17.7% | — | 7.9% |
|
TMO
Thermo Fisher Scientific Inc.
|
$225.93B | +5.2% | +14.5% | 32.9 | 1.5% |
|
DHR
Danaher Corp /De/
|
$140.70B | -12.6% | +8.5% | 35.5 | 1.4% |
|
NTRA
Natera, Inc.
|
$47.01B | +43.6% | -2.8% | — | 3.8% |
|
IQV
Iqvia Holdings Inc.
|
$42.94B | +16.1% | +41.6% | 32.0 | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PSNL | -3.7% | +12.4% | +123.3% | -3.4% | +103.6% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | -2.5% | +14.2% | +105.4% | -3.0% | +91.6% |
Key facts
CIK
1527753
CUSIP
71535D106
13F (30d)
83 filings
83 filers
Visit website
Investor relations